Active Biotech AB Interim Report January-June 2008

Active Biotech (ACTI.ST) * Laquinimod - enrolment for the Allegro and Bravo Phase III studies proceeding * ANYARA - Phase III study proceeding - Promising median survival from Phase I study * TASQ - Phase II studies for treatment of prostate cancer in progress * 57-57 - Phase Ib study against SLE successfully concluded * RhuDex® - Phase IIa study against RA presented positive findings * Tomas Leanderson new CEO from September 1 * Net sales SEK 5.8 M (5.8) * Operating result SEK -104.7 M (-108.5) * Result after tax SEK -99.3 M (-112.1) * Result per share for the period amounted to SEK -2.07 (-2.46)

Comments from President & CEO Sven Andréasson: "Enrolment for another clinical Phase III study for laquinimod started during the period and complete Phase II data was published in the respected medical journal The Lancet. The planned interim analysis from the first part of the Phase II/III trial for the ANYARA cancer project presented positive data and the pivotal Phase III study commenced in May. We now have two Phase III projects and three clinical Phase II projects. Consequently, we have further strengthened Active Biotech's position as a company with a balanced and mature project portfolio."

For further information, please contact: Sven Andréasson President & CEO Tel: +46 (0)46-19 20 49

Göran Forsberg VP Communication & Business Development Tel: +46 (0)46-19 11 54

Hans Kolam

Active Biotech AB CFO (Corp. Reg. No. 556223-9227) Tel +46 (0)46-19 20 44 PO Box 724, SE-220 07 Lund

Tel +46 (0)46-19 20 00 Fax +46 (0)46-19 20 50 This report is also available at www.activebiotech.com



LINK: http://hugin.info/1002/R/1241001/266339.pdf

Active Biotech

http://www.activebiotech.com/

ISIN: SE0001137985

Stock Identifier: XOME.ACTI

US: ACTI.ST